Sinocare(SZ:300298) Xin Lang Cai Jing·2026-02-26 01:29Group 1 - The core viewpoint of the news is that Sanofi Bio's stock performance and financing activities indicate a mixed market sentiment, with a slight increase in stock price but a net outflow in financing [1] - On February 25, Sanofi Bio's stock rose by 1.22%, with a trading volume of 114 million yuan, while the net financing buy was negative at -861.93 million yuan, indicating a higher repayment than new purchases [1] - As of February 25, the total balance of margin trading for Sanofi Bio was 342 million yuan, with a financing balance of 340 million yuan, representing 3.34% of the circulating market value, which is below the 50th percentile of the past year [1] Group 2 - Sanofi Bio, established on August 7, 2002, specializes in the research, design, production, and sales of point-of-care testing (POCT) products for chronic diseases, with a significant revenue contribution from blood glucose monitoring systems at 73.29% [2] - For the period from January to September 2025, Sanofi Bio reported a revenue of 3.453 billion yuan, reflecting a year-on-year growth of 8.52%, while the net profit attributable to shareholders decreased by 17.36% to 211 million yuan [2] - The company has distributed a total of 1.512 billion yuan in dividends since its A-share listing, with 344 million yuan distributed in the last three years [3]